Study wrapper · #1128
Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.
Editor's note
Spontaneous-reporting databases capture what clinicians and patients choose to file, not what actually happens in a population, so a reporting odds ratio near 1.5 on roughly 50 reports is a weak observation by design. Confounding by indication is severe here: diabetes itself is a leading cause of erectile dysfunction, and no denominator or comorbidity adjustment is possible in this data. The authors are appropriately explicit that this establishes no causal link and is hypothesis-generating only.
Plain-language abstract
Researchers mined the FDA Adverse Event Reporting System for reports of erectile dysfunction linked to common diabetes medications, using disproportionality analysis to see which drugs generate more such reports than expected. Semaglutide (49 reports), sitagliptin (54), and dapagliflozin (42) each showed a modest statistical signal, with reporting odds ratios around 1.5. Timing analysis suggested onset was scattered across the course of therapy rather than clustered early. Dulaglutide, linagliptin, and metformin showed no signal.